UK group to drive "universal access" to prostate LDR (low-dose-rate) brachytherapy:
This article was originally published in Clinica
The UK National Health Service (NHS) has formally established a prostate brachytherapy advisory group to steer service development in this specialism. The group's main aim will be to "support universal access to low-dose-rate (LDR) brachytherapy in the UK", by: optimising the use of services within radiotherapy centres that currently perform the technique; helping to commission services not available locally; and promoting best practice and evidence-based approaches, sourced in the UK and internationally.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.